Earnings History Data for Innate Pharma S.A. (IPHA) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Innate Pharma S.A.
Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-11-2024 | PM | IPHA | Innate Pharma S.A. | 148.84 | N/A | 0.00 | 0.00 | Innate Pharma reports 9M results [11/13/2024 10:39 AM] |
1.70 | -0.20 (-10.53%) |
0.0 | 0.0 (0.00%) |
1.57 - 3.15 | 3,713 | 10,000 | 0 | ||
| 12-09-2024 | PM | IPHA | Innate Pharma S.A. | 191.48 | N/A | 0.00 | 0.00 | Innate Pharma GAAP EPS of -€0.31, revenue of €12.35M [9/12/2024 1:15 AM] |
2.28 | -0.08 (-3.39%) |
2.29 | -0.07 (-2.97%) |
1.81 - 3.15 | 7,732 | 0 | 492 | ||
| 14-05-2024 | PM | IPHA | Innate Pharma S.A. | 203.55 | N/A | 0.00 | 0.00 | Innate Pharma reports Q1 results [5/14/2024 10:18 AM] |
2.50 | -0.10 (-4.02%) |
2.49 | -0.12 (-4.59%) |
1.81 - 3.57 | 2,785 | 0 | 7,574 | ||
| 21-03-2024 | PM | IPHA | Innate Pharma S.A. | 190.11 | N/A | 0.00 | 0.00 | Innate Pharma GAAP EPS of -€0.09, revenue of €61.64M [3/21/2024 5:21 AM] |
2.41 | -0.09 (-3.60%) |
2.41 | -0.09 (-3.60%) |
1.81 - 3.57 | 10,172 | 10,000 | 1,264 | ||
| 14-11-2023 | PM | IPHA | Innate Pharma S.A. | 188.52 | N/A | 0.00 | 0.00 | Innate Pharma reports results for the first nine months [11/14/2023 2:33 AM] |
2.58 | 0.31 (13.66%) |
0.0 | 0.0 (0.00%) |
1.81 - 3.97 | 29,565 | 30,000 | 0 | ||
| 23-03-2023 | PM | Before the open (Mar 23) |
IPHA | Innate Pharma S.A. | 247.05 | N/A | 0.00 | 0.00 | Innate Pharma GAAP EPS of -€0.73, revenue of €57.67M [3/23/2023 2:21 AM] |
2.95 | -0.08 (-2.64%) |
0.0 | 0.0 (0.00%) |
1.90 - 3.97 | 4,252 | 20,000 | 0 | |
| 24-03-2022 | PM | IPHA | Innate Pharma S.A. | 267.03 | N/A | 0.00 | 0.00 | Innate Pharma GAAP EPS of -€0.66, revenue of €24.7M [3/24/2022 2:33 AM] |
3.29 | -0.18 (-5.19%) |
3.39 | -0.08 (-2.31%) |
2.66 - 11.95 | 11,581 | 41,121 | 0 | ||
| 11-05-2021 | PM | Before the open (May 11) |
IPHA | Innate Pharma S.A. | 312.04 | N/A | 0.00 | 0.00 | Innate Pharma reports Q1 results [5/11/2021 3:46 AM] |
4.04 | 0.18 (4.66%) |
4.07 | 0.21 (5.44%) |
3.55 - 8.23 | 3,262 | 0 | 865 | |